OncoMatch/Clinical Trials/Bile Duct Cancer (Cholangiocarcinoma)
Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials
OncoMatch filters Bile Duct Cancer (Cholangiocarcinoma) trials by the molecular markers that determine eligibility — FGFR2, IDH1, IDH2, BRAF, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Bile Duct Cancer (Cholangiocarcinoma) trials
These are the molecular markers most commonly required or evaluated in Bile Duct Cancer (Cholangiocarcinoma) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Bile Duct Cancer (Cholangiocarcinoma) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
AstraZeneca
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
AstraZeneca
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
J-Pharma Co., Ltd.
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
How OncoMatch finds Bile Duct Cancer (Cholangiocarcinoma) trials for you
AI reads the protocol
Every Bile Duct Cancer (Cholangiocarcinoma) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Bile Duct Cancer (Cholangiocarcinoma) and mark your biomarker results — FGFR2, IDH1, IDH2 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.